SI-BONE, Inc. (SIBN)
| Market Cap | 733.96M |
| Revenue (ttm) | 85.15M |
| Net Income (ttm) | -44.68M |
| Shares Out | 32.98M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120,065 |
| Open | 22.13 |
| Previous Close | 22.22 |
| Day's Range | 21.64 - 22.37 |
| 52-Week Range | 19.26 - 37.21 |
| Beta | 1.43 |
| Analysts | Strong Buy |
| Price Target | 38.86 (+76.2%) |
| Est. Earnings Date | Nov 8, 2021 |
About SIBN
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Financial Performance
In 2020, SI-BONE, Inc.'s revenue was $73.39 million, an increase of 9.04% compared to the previous year's $67.30 million. Losses were -$43.70 million, 13.8% more than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SI-BONE, Inc. stock is "Strong Buy." The 12-month stock price forecast is 38.86, which is an increase of 76.16% from the latest price.
News
SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021
SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...
SI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion
The transition to an exclusive triangular implant policy by UnitedHealthcare, the nation's largest health insurer, is supported by over 100+ peer-reviewed publications, and comes as SI-BONE surpasses 60...
SI-BONE to Participate in Upcoming Conferences
SANTA CLARA, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced t...
SI-BONE Q2 Sales Beat Estimates But Higher Costs Hit Profitability, Maintains FY21 Revenue Outlook
SI-BONE Inc (NASDAQ: SIBN) reported Q2 sales of $22.2 million, beating the consensus of $21.96 million, representing a 58% Y/Y increase over the COVID-19 impacted 2020 period. U.S. revenue of $20.2 mill...
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of -7.69% and 0.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE: Q2 Earnings Insights
Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.55% over the past year to ($0.42), which missed ...
SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem
Record Second Quarter 2021 Worldwide Revenue of $22.2 million Record Second Quarter 2021 Worldwide Revenue of $22.2 million
SI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangul...
Anthem is America's 2nd largest commercial health insurer and joins more than 35 other health plans to offer coverage exclusively for the triangular iFuse Implant System Anthem is America's 2nd largest ...
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE To Report Second Quarter 2021 Financial Results on August 2, 2021
SANTA CLARA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...
SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse ...
New positive coverage policy provides access to iFuse as an important treatment option for patients with chronic sacroiliac joint pain and dysfunction New positive coverage policy provides access to iFu...
SI-BONE's Sacroiliac Joint Implant Show Accelerated Fusion, Reduction In Opioid Use
SI-BONE Inc (NASDAQ: SIBN) has announced the publication of 2-year results from the SALLY study of the iFuse-3D Implant System. Clinical results at 24 months showed marked and sustained improvements in...
SI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate ...
There are now 95 peer-reviewed publications demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™ There are now 95 peer-reviewed publications demonstrating the...
SI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training a...
SANTA CLARA, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anat...
French National Healthcare System Adopts Exclusive Reimbursement Policy for SI-BONE, Inc.'s iFuse-3D Implant System™
Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years
SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference
SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced t...
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of 2.63% and 7.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: SI-BONE Q1 Earnings
Shares of SI-BONE (NASDAQ:SIBN) remained quited after the company reported Q1 results. Quarterly Results Earnings per share were up 21.28% year over year to ($0.37), which beat the estimate of ($0.39).
SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance
SANTA CLARA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fina...
SI-BONE to Present at the 7th Annual Truist 2021 Life Sciences Summit and the 2021 Bank of America Health Care Confer...
SANTA CLARA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced ...
SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Franc...
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic ana...
SI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021
SANTA CLARA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced ...
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of 6.67% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: SI-BONE Q4 Earnings
Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.22% year over year to ($0.28), which beat the estima...
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance
SANTA CLARA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fi...